Clinical Trial Update: Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer [Phase 3]

View source ↗

Summary

An Italian multicenter Phase 3 trial compares FOLFOXIRI against Gemcitabine as adjuvant therapy after resection of pancreatic cancer; the status is currently UN…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Azienda Ospedaliero, Universitaria Pisana | Conditions: Pancreatic Cancer | Phase 3 | Status: UNKNOWN